Pfizer Stock Appears Undervalued Despite Recent Gains, May Offer Long-Term Value

Pfizer's stock appears undervalued compared to its GF Value despite recent gains. The GF Value estimates a fair value of $50 based on historical multiples and future growth.

Pfizer has fair financial strength with strong profitability. Its revenue was $77B in the past year with 30% operating margin.

Pfizer's growth ranks above 76% of drug companies. Its 3-year revenue growth is 34% and EBITDA growth 30%.

Pfizer generates higher returns on capital than its cost of capital, indicating profitable reinvestment.

In summary, Pfizer seems undervalued given its financials and growth. Its stock may deliver above-average long-term returns.